Safety Protocol Deviation Liability

Introduction

Safety protocol deviation liability refers to the legal responsibility arising when a person, institution, or company fails to follow prescribed safety procedures and that failure causes injury, illness, environmental harm, or other legally recognised damage. In biotechnology, such deviations may occur during clinical trials, genetic research, vaccine production, laboratory handling, biomedical waste disposal, or the use of genetically modified organisms.

The concept is not a separate, universally recognised legal doctrine. Rather, liability is determined through established principles of negligence, statutory compliance, product liability, informed consent, and public safety. A deviation may be justified in an emergency, but it must be supported by scientific reasons, proper documentation, and safeguards against avoidable harm.

Legal Framework in India

The principal legal framework includes:

New Drugs and Clinical Trials Rules, 2019: Rule 41 treats injury, death, or permanent disability caused by violation of an approved clinical-trial protocol, scientific misconduct, or negligence leading to a serious adverse event as trial-related. The rules also provide for medical management and compensation in qualifying cases.

CDSCO+1

Negligence under tort law: Liability generally requires a duty of care, breach of that duty, and resulting damage. A protocol deviation alone may not establish liability unless the legal elements are satisfied.

Consumer protection and civil remedies: A patient or research participant may seek compensation where deficient services or negligent conduct cause legally cognisable harm.

Regulatory consequences: Serious non-compliance may lead to suspension or cancellation of trial permissions, restrictions on future trials, or other regulatory action.

CDSCO

Case Laws

1. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1

The Supreme Court explained the standard for professional negligence. A professional must possess the required skill and exercise reasonable competence. Mere error of judgment or departure from a usual practice does not automatically establish negligence; the circumstances and accepted standards of care must be examined. This principle is relevant when assessing whether a biotechnology researcher or clinician’s deviation from a safety protocol was unreasonable.

Supreme Court+1

2. Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651

The Supreme Court recognised that medical services may fall within consumer-protection law, subject to the conditions explained in the judgment. In biotechnology-related treatment or clinical research, deficient professional services may therefore support a consumer claim where the statutory requirements are met. The case does not itself decide research-protocol deviation, but provides an important route for civil accountability.

VoxJuris

3. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

The Supreme Court emphasised informed consent and the limits of consent for medical procedures. In a clinical-trial setting, a material change to a procedure or risk profile may require appropriate consent and ethical review. A protocol deviation that exposes a participant to an undisclosed risk can therefore raise consent-related concerns, depending on the facts.

SCI API

Determining Liability

A court or regulator should consider:

Whether the protocol was approved and applicable.

Whether the deviation was deliberate, negligent, or medically justified.

Whether prior approval or informed consent was required.

Whether the deviation caused or contributed to injury.

Whether the institution documented the event and took corrective action.

Whether the sponsor, investigator, laboratory, or institution had responsibility for the breach.

A justified emergency departure from protocol should be distinguished from an avoidable violation. However, the emergency rationale must be genuine, proportionate, and properly recorded.

Conclusion

Safety protocol deviation liability is an important mechanism for protecting research participants, patients, laboratory workers, and the public. Indian law does not impose automatic liability for every deviation. Instead, responsibility depends on the applicable statutory rules, the nature of the breach, causation, and the standard of care. In clinical trials, Rule 41 of the New Drugs and Clinical Trials Rules, 2019 is especially significant because it expressly recognises serious adverse events caused by protocol violations, scientific misconduct, or negligence as trial-related injuries.

CDSCO+1